Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003403 · ClinicalTrials.gov registry record · Phase 1

GPX-100 in Treating Patients With Solid Tumors

A Phase 1 study, sponsored by Gem Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase

NCT00003403: Completed Phase 1 study, sponsored by Gem Pharmaceuticals.

NCT00003403 is a Phase 1 study that has completed, run by Gem Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003403, a Phase 1 study, has completed, sponsored by Gem Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.

Interventions

  • DRUG GPX-100

Trial Details

FieldValue
Start Date 1999-08
Phase Phase 1
Gem Pharmaceuticals

4 total trials

What the finished NCT00003403 record still lists

NCT00003403 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which GPX-100 is the first listed.

NCT00003403 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00003403 about?

NCT00003403 is a clinical study titled "GPX-100 in Treating Patients With Solid Tumors". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.

What is the current status of trial NCT00003403?

This trial is currently completed. It is a Phase 1 study. The study started on 1999-08.

What interventions are being tested in trial NCT00003403?

The interventions under investigation include: GPX-100 (DRUG).

Who is sponsoring clinical trial NCT00003403?

This trial is sponsored by Gem Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003403, the US trial registry maintained by the National Library of Medicine. NCT00003403 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.